Veracyte, Inc. (NASDAQ: VCYT) Stock Competitors & Peer Comparison
See VCYT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for VCYT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VCYT | $45.43 | -6.41% | 3.6B | 22.72 | $2.00 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.64% |
| TMO | $675.00 | -0.50% | 249.1B | 29.09 | $23.16 | +0.27% |
| DHR | $224.49 | +0.32% | 157.8B | 28.14 | $7.98 | +0.64% |
| NTRA | $412.56 | +0.92% | 59.1B | -312.55 | -$1.32 | N/A |
| A | $172.79 | -0.03% | 48.8B | 29.74 | $5.81 | +0.59% |
| IQV | $270.37 | -1.69% | 44.4B | 22.24 | $12.13 | N/A |
| WAT | $433.54 | +0.75% | 42.6B | 31.71 | $13.68 | N/A |
| IDXX | $519.26 | +1.14% | 41B | 36.52 | $14.22 | N/A |
| ILMN | $270.00 | -1.42% | 40.9B | 53.68 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
VCYT vs DHR-PB Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, VCYT's ROE is +0.09%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, VCYT is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
VCYT vs TMO Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, TMO has a market cap of 249.1B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while TMO trades at $675.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas TMO's P/E ratio is 29.09. In terms of profitability, VCYT's ROE is +0.09%, compared to TMO's ROE of +0.13%. Regarding short-term risk, VCYT is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
VCYT vs DHR Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, DHR has a market cap of 157.8B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while DHR trades at $224.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas DHR's P/E ratio is 28.14. In terms of profitability, VCYT's ROE is +0.09%, compared to DHR's ROE of +0.08%. Regarding short-term risk, VCYT is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
VCYT vs NTRA Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, NTRA has a market cap of 59.1B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while NTRA trades at $412.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas NTRA's P/E ratio is -312.55. In terms of profitability, VCYT's ROE is +0.09%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, VCYT is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
VCYT vs A Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, A has a market cap of 48.8B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while A trades at $172.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas A's P/E ratio is 29.74. In terms of profitability, VCYT's ROE is +0.09%, compared to A's ROE of +0.20%. Regarding short-term risk, VCYT is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
VCYT vs IQV Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while IQV trades at $270.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas IQV's P/E ratio is 22.24. In terms of profitability, VCYT's ROE is +0.09%, compared to IQV's ROE of +0.22%. Regarding short-term risk, VCYT is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check IQV's competition here
Waters Corporation (NYSE: WAT)
VCYT vs WAT Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, WAT has a market cap of 42.6B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while WAT trades at $433.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas WAT's P/E ratio is 31.71. In terms of profitability, VCYT's ROE is +0.09%, compared to WAT's ROE of +0.02%. Regarding short-term risk, VCYT is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
VCYT vs IDXX Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, IDXX has a market cap of 41B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while IDXX trades at $519.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas IDXX's P/E ratio is 36.52. In terms of profitability, VCYT's ROE is +0.09%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, VCYT is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
VCYT vs ILMN Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, ILMN has a market cap of 40.9B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while ILMN trades at $270.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas ILMN's P/E ratio is 53.68. In terms of profitability, VCYT's ROE is +0.09%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, VCYT is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
VCYT vs MTD Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, MTD has a market cap of 30.5B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while MTD trades at $1,511.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas MTD's P/E ratio is 34.73. In terms of profitability, VCYT's ROE is +0.09%, compared to MTD's ROE of -12.00%. Regarding short-term risk, VCYT is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
VCYT vs DGX Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, DGX has a market cap of 26.1B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while DGX trades at $236.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas DGX's P/E ratio is 23.30. In terms of profitability, VCYT's ROE is +0.09%, compared to DGX's ROE of +0.14%. Regarding short-term risk, VCYT is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
VCYT vs LH Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while LH trades at $309.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas LH's P/E ratio is 18.37. In terms of profitability, VCYT's ROE is +0.09%, compared to LH's ROE of +0.12%. Regarding short-term risk, VCYT is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
VCYT vs GH Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, GH has a market cap of 23.7B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while GH trades at $177.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas GH's P/E ratio is -50.56. In terms of profitability, VCYT's ROE is +0.09%, compared to GH's ROE of +2.11%. Regarding short-term risk, VCYT is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
VCYT vs EXAS Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas EXAS's P/E ratio is -95.37. In terms of profitability, VCYT's ROE is +0.09%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, VCYT is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
VCYT vs MEDP Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while MEDP trades at $618.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas MEDP's P/E ratio is 36.28. In terms of profitability, VCYT's ROE is +0.09%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, VCYT is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
VCYT vs ILMNV Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas ILMNV's P/E ratio is N/A. In terms of profitability, VCYT's ROE is +0.09%, compared to ILMNV's ROE of N/A. Regarding short-term risk, VCYT is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
VCYT vs RVTY Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, RVTY has a market cap of 16.9B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while RVTY trades at $151.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas RVTY's P/E ratio is 28.24. In terms of profitability, VCYT's ROE is +0.09%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, VCYT is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
VCYT vs PKI Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas PKI's P/E ratio is 41.45. In terms of profitability, VCYT's ROE is +0.09%, compared to PKI's ROE of +0.03%. Regarding short-term risk, VCYT is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
VCYT vs CRL Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, CRL has a market cap of 14.1B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while CRL trades at $292.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas CRL's P/E ratio is 29.61. In terms of profitability, VCYT's ROE is +0.09%, compared to CRL's ROE of -0.08%. Regarding short-term risk, VCYT is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
VCYT vs ICLR Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while ICLR trades at $172.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas ICLR's P/E ratio is 14.06. In terms of profitability, VCYT's ROE is +0.09%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, VCYT is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
VCYT vs QGEN Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, QGEN has a market cap of 9.1B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while QGEN trades at $44.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas QGEN's P/E ratio is 18.25. In terms of profitability, VCYT's ROE is +0.09%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, VCYT is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check QGEN's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
VCYT vs BLLN Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, BLLN has a market cap of 5.7B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while BLLN trades at $123.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas BLLN's P/E ratio is 175.83. In terms of profitability, VCYT's ROE is +0.09%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, VCYT is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check BLLN's competition here
RadNet, Inc. (NASDAQ: RDNT)
VCYT vs RDNT Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while RDNT trades at $70.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas RDNT's P/E ratio is 153.89. In terms of profitability, VCYT's ROE is +0.09%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, VCYT is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
VCYT vs GRAL Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, GRAL has a market cap of 5.4B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while GRAL trades at $126.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas GRAL's P/E ratio is -12.83. In terms of profitability, VCYT's ROE is +0.09%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, VCYT is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check GRAL's competition here
Sotera Health Company (NASDAQ: SHC)
VCYT vs SHC Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while SHC trades at $18.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas SHC's P/E ratio is 19.10. In terms of profitability, VCYT's ROE is +0.09%, compared to SHC's ROE of +0.27%. Regarding short-term risk, VCYT is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
VCYT vs SYNH Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas SYNH's P/E ratio is 61.40. In terms of profitability, VCYT's ROE is +0.09%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, VCYT is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check SYNH's competition here
CareDx, Inc (NASDAQ: CDNA)
VCYT vs CDNA Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while CDNA trades at $63.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas CDNA's P/E ratio is 75.81. In terms of profitability, VCYT's ROE is +0.09%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, VCYT is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
VCYT vs OLK Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas OLK's P/E ratio is -96.59. In terms of profitability, VCYT's ROE is +0.09%, compared to OLK's ROE of -0.07%. Regarding short-term risk, VCYT is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
VCYT vs WGS Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while WGS trades at $88.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas WGS's P/E ratio is 245.56. In terms of profitability, VCYT's ROE is +0.09%, compared to WGS's ROE of -0.39%. Regarding short-term risk, VCYT is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
VCYT vs PSNL Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, PSNL has a market cap of 1.8B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while PSNL trades at $16.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas PSNL's P/E ratio is -15.10. In terms of profitability, VCYT's ROE is +0.09%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, VCYT is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
VCYT vs OPK Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas OPK's P/E ratio is -6.07. In terms of profitability, VCYT's ROE is +0.09%, compared to OPK's ROE of -0.06%. Regarding short-term risk, VCYT is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
VCYT vs CSTL Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while CSTL trades at $35.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas CSTL's P/E ratio is -54.26. In terms of profitability, VCYT's ROE is +0.09%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, VCYT is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
VCYT vs FLGT Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, FLGT has a market cap of 630.5M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while FLGT trades at $22.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas FLGT's P/E ratio is 2220.00. In terms of profitability, VCYT's ROE is +0.09%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, VCYT is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
VCYT vs GRALV Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas GRALV's P/E ratio is N/A. In terms of profitability, VCYT's ROE is +0.09%, compared to GRALV's ROE of N/A. Regarding short-term risk, VCYT is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
VCYT vs NEO Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, NEO has a market cap of 496.7M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while NEO trades at $19.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas NEO's P/E ratio is 148.69. In terms of profitability, VCYT's ROE is +0.09%, compared to NEO's ROE of -0.06%. Regarding short-term risk, VCYT is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
VCYT vs CO Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas CO's P/E ratio is 5.06. In terms of profitability, VCYT's ROE is +0.09%, compared to CO's ROE of +0.11%. Regarding short-term risk, VCYT is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
VCYT vs MYGN Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, MYGN has a market cap of 393.8M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while MYGN trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas MYGN's P/E ratio is -32.08. In terms of profitability, VCYT's ROE is +0.09%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, VCYT is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
VCYT vs FLDM Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas FLDM's P/E ratio is -4.74. In terms of profitability, VCYT's ROE is +0.09%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, VCYT is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
VCYT vs BDSX Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, BDSX has a market cap of 236.9M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while BDSX trades at $29.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas BDSX's P/E ratio is -9.18. In terms of profitability, VCYT's ROE is +0.09%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, VCYT is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
VCYT vs XGN Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, XGN has a market cap of 210.7M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while XGN trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas XGN's P/E ratio is -10.77. In terms of profitability, VCYT's ROE is +0.09%, compared to XGN's ROE of -1.22%. Regarding short-term risk, VCYT is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
VCYT vs FRNM Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, FRNM has a market cap of 130.4M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while FRNM trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas FRNM's P/E ratio is N/A. In terms of profitability, VCYT's ROE is +0.09%, compared to FRNM's ROE of N/A. Regarding short-term risk, VCYT is more volatile compared to FRNM. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
VCYT vs GTH Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas GTH's P/E ratio is -1.11. In terms of profitability, VCYT's ROE is +0.09%, compared to GTH's ROE of -1.01%. Regarding short-term risk, VCYT is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check GTH's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
VCYT vs IMDX Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, IMDX has a market cap of 126.6M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while IMDX trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas IMDX's P/E ratio is -2.63. In terms of profitability, VCYT's ROE is +0.09%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, VCYT is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check IMDX's competition here
Genetic Technologies Limited (NASDAQ: GENE)
VCYT vs GENE Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas GENE's P/E ratio is -38.25. In terms of profitability, VCYT's ROE is +0.09%, compared to GENE's ROE of -1.85%. Regarding short-term risk, VCYT is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
VCYT vs SERA Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, SERA has a market cap of 77.9M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while SERA trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas SERA's P/E ratio is -3.14. In terms of profitability, VCYT's ROE is +0.09%, compared to SERA's ROE of -0.47%. Regarding short-term risk, VCYT is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
VCYT vs PRPO Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, PRPO has a market cap of 42.2M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while PRPO trades at $23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas PRPO's P/E ratio is -36.38. In terms of profitability, VCYT's ROE is +0.09%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, VCYT is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
VCYT vs QUCY Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, QUCY has a market cap of 31.4M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while QUCY trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas QUCY's P/E ratio is -0.06. In terms of profitability, VCYT's ROE is +0.09%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, VCYT is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
VCYT vs MDXH Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, MDXH has a market cap of 29M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while MDXH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas MDXH's P/E ratio is -0.77. In terms of profitability, VCYT's ROE is +0.09%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, VCYT is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
VCYT vs AKU Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas AKU's P/E ratio is -0.13. In terms of profitability, VCYT's ROE is +0.09%, compared to AKU's ROE of -5.32%. Regarding short-term risk, VCYT is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
VCYT vs BNR Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, BNR has a market cap of 19.7M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while BNR trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas BNR's P/E ratio is -21.38. In terms of profitability, VCYT's ROE is +0.09%, compared to BNR's ROE of -0.13%. Regarding short-term risk, VCYT is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
VCYT vs CEMI Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas CEMI's P/E ratio is -0.63. In terms of profitability, VCYT's ROE is +0.09%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, VCYT is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
VCYT vs ENZ Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas ENZ's P/E ratio is -2.24. In terms of profitability, VCYT's ROE is +0.09%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, VCYT is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
VCYT vs PMD Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas PMD's P/E ratio is -5.24. In terms of profitability, VCYT's ROE is +0.09%, compared to PMD's ROE of -0.32%. Regarding short-term risk, VCYT is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
VCYT vs ME Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas ME's P/E ratio is -0.03. In terms of profitability, VCYT's ROE is +0.09%, compared to ME's ROE of -42.03%. Regarding short-term risk, VCYT is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
VCYT vs MYNZ Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, VCYT's ROE is +0.09%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, VCYT is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check MYNZ's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
VCYT vs CHEK Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas CHEK's P/E ratio is -0.43. In terms of profitability, VCYT's ROE is +0.09%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, VCYT is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check CHEK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
VCYT vs BIAFW Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, BIAFW has a market cap of 9.6M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while BIAFW trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas BIAFW's P/E ratio is 1.02. In terms of profitability, VCYT's ROE is +0.09%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, VCYT is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check BIAFW's competition here
Centogene N.V. (NASDAQ: CNTG)
VCYT vs CNTG Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas CNTG's P/E ratio is -0.23. In terms of profitability, VCYT's ROE is +0.09%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, VCYT is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
VCYT vs ADVB Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, ADVB has a market cap of 8.8M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while ADVB trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas ADVB's P/E ratio is -58.00. In terms of profitability, VCYT's ROE is +0.09%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, VCYT is more volatile compared to ADVB. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
VCYT vs NDRA Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while NDRA trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas NDRA's P/E ratio is -0.90. In terms of profitability, VCYT's ROE is +0.09%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, VCYT is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
VCYT vs APDN Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas APDN's P/E ratio is -0.10. In terms of profitability, VCYT's ROE is +0.09%, compared to APDN's ROE of -7.23%. Regarding short-term risk, VCYT is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
VCYT vs NVTA Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas NVTA's P/E ratio is -0.00. In terms of profitability, VCYT's ROE is +0.09%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, VCYT is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
VCYT vs LMDXW Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, VCYT's ROE is +0.09%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, VCYT is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
VCYT vs LMDX Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas LMDX's P/E ratio is -0.01. In terms of profitability, VCYT's ROE is +0.09%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, VCYT is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check LMDX's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
VCYT vs BIAF Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, BIAF has a market cap of 3.3M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while BIAF trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas BIAF's P/E ratio is -0.93. In terms of profitability, VCYT's ROE is +0.09%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, VCYT is more volatile compared to BIAF. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check BIAF's competition here
DermTech, Inc. (NASDAQ: DMTK)
VCYT vs DMTK Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas DMTK's P/E ratio is -0.04. In terms of profitability, VCYT's ROE is +0.09%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, VCYT is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
VCYT vs NOTV Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas NOTV's P/E ratio is -0.03. In terms of profitability, VCYT's ROE is +0.09%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, VCYT is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
VCYT vs SQL Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas SQL's P/E ratio is -0.40. In terms of profitability, VCYT's ROE is +0.09%, compared to SQL's ROE of -30.46%. Regarding short-term risk, VCYT is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
VCYT vs AWH Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas AWH's P/E ratio is -0.09. In terms of profitability, VCYT's ROE is +0.09%, compared to AWH's ROE of +1.62%. Regarding short-term risk, VCYT is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
VCYT vs HTGM Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas HTGM's P/E ratio is -0.03. In terms of profitability, VCYT's ROE is +0.09%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, VCYT is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
VCYT vs BIOC Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas BIOC's P/E ratio is -0.01. In terms of profitability, VCYT's ROE is +0.09%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, VCYT is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
VCYT vs SQLLW Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, VCYT's ROE is +0.09%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, VCYT is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check SQLLW's competition here
iSpecimen Inc. (NASDAQ: ISPC)
VCYT vs ISPC Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, ISPC has a market cap of 175K. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while ISPC trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas ISPC's P/E ratio is -0.04. In terms of profitability, VCYT's ROE is +0.09%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, VCYT is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check ISPC's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
VCYT vs WGSWW Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, VCYT's ROE is +0.09%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, VCYT is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check WGSWW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
VCYT vs PRXL Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas PRXL's P/E ratio is 42.97. In terms of profitability, VCYT's ROE is +0.09%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, VCYT is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check PRXL's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
VCYT vs OCDX Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas OCDX's P/E ratio is -42.28. In terms of profitability, VCYT's ROE is +0.09%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, VCYT is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
VCYT vs BNGOW Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas BNGOW's P/E ratio is N/A. In terms of profitability, VCYT's ROE is +0.09%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, VCYT is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check BNGOW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
VCYT vs NDRAW Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas NDRAW's P/E ratio is N/A. In terms of profitability, VCYT's ROE is +0.09%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, VCYT is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check NDRAW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
VCYT vs MEUSW Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas MEUSW's P/E ratio is N/A. In terms of profitability, VCYT's ROE is +0.09%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, VCYT is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check MEUSW's competition here
Danaher Corporation (NYSE: DHR-PA)
VCYT vs DHR-PA Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, VCYT's ROE is +0.09%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, VCYT is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for VCYT.Check DHR-PA's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
VCYT vs CHEKZ Comparison September 2026
Veracyte, Inc. (NASDAQ: VCYT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCYT stands at 3.6B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, VCYT is priced at $45.43 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCYT currently has a P/E ratio of 22.72, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, VCYT's ROE is +0.09%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, VCYT is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for VCYT.Check CHEKZ's competition here